Triple-negative breast cancers (TNBCs) are aggressive tumors that account for 15% of all new breast cancer (BC) diagnoses. However, they are negative for the expression of ER-Ξ±, PR, or HER2. This molecular heterogeneity of triple-negative breast cancer or TNBC and subtype-specific differences limit the effectiveness of the current targeted therapies. Scientists from the University of Texas have developed an oncotherapeutic molecule that targets previously missed vulnerable sites in TNBC.
In addition, the novel molecule is not harmful to healthy mammary tissue. Findings of the study: Newly discovered TNBC target β Lysosomal acid lipase A (LIPA)Β Novel stereospecific LIPA-binding molecule β ERX-41 ERX-41 induces endoplasmic reticulum stress and apoptosis, thereby hindering resistance-enabling LIPA mutations and rendering the TNBC vulnerable to target therapy. ERX-41 does not harm healthyβ¦
